Home
HelpTest Code TREGS T-Cell Subsets, Regulatory (Tregs), Blood
Reporting Name
T Cell Subsets, Regulatory (Tregs)Performing Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Evaluating patients with clinical features of IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked inheritance) and other primary immunodeficiencies, autoimmune diseases, allergy and asthma, and graft-vs-host disease post-hematopoietic stem cell transplantation
Method Name
Flow Cytometry
Shipping Instructions
Testing performed Monday through Friday. Specimens not received by 4 p.m. Central time on Fridays may be canceled
Specimens arriving on the weekend and observed holidays may be canceled.
Collect and package specimen as close to shipping time as possible. It is recommended that specimens arrive within 24 hours of collection.
Necessary Information
The ordering healthcare professional's name and phone number are required.
Specimen Required
Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Additional Information: For serial monitoring, it is recommended that specimens are collected at the same time of day.
Specimen Type
Whole Blood EDTASpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Ambient | 72 hours | PURPLE OR PINK TOP/EDTA |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
Reference Values
The appropriate age-related reference values will be provided on the report.
Interpretation
The lack of regulatory T cells (Tregs) is associated with variants in the FOXP3 gene. Low Tregs are also seen in the context of other inborn errors of immunity. Reduced Nn Tregs and natural Tregs are likely to predispose to autoimmunity, while reductions in Th3/Tr1 cells may impair oral and peripheral tolerance, also facilitating the development of autoimmunity.
The presence of expanded naive Tregs may indicate a process of malignant transformation, if other clinical features of malignant disease are present.
Increased Tregs in donor stem cell allografts have been associated with a reduced incidence of graft-versus-host disease (ie, mediating a protective effect) after allogeneic stem cell transplantation.
Day(s) Performed
Monday through Friday
Report Available
3 to 4 daysTest Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86359
86361
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| TREGS | T Cell Subsets, Regulatory (Tregs) | 90413-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 609282 | CD4 (T Cells) | 24467-3 |
| 29143 | % Activated CD4+ T cells (4+CD25+) | 13332-2 |
| 29144 | % Natural Tregs | 89320-6 |
| 29145 | % N. Naive Tregs | 89319-8 |
| 29146 | % CD4+CD25-CD127+ (Tr1/Th3) | 89318-0 |
| 29147 | Activated CD4+ T cells (4+CD25+) | 26982-9 |
| 29148 | CD4+CD25+CD127loCD45RO+ (Nat Tregs) | 89316-4 |
| 29149 | CD4+CD25+CD127loCD45RA+ Naive Tregs | 89315-6 |
| 29150 | CD4+CD25-CD127+ (Tr1/Th3) | 89317-2 |
| 29177 | Interpretation | 69052-9 |